- Home
- AGIO vs PTEN Comparison
AGIO vs PTEN Comparison
Compare AGIO & PTEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- PTEN
- Stock Information
- Founded
- AGIO 2007
- PTEN 1978
- Country
- AGIO United States
- PTEN United States
- Employees
- AGIO N/A
- PTEN N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- PTEN Oil & Gas Production
- Sector
- AGIO Health Care
- PTEN Energy
- Exchange
- AGIO Nasdaq
- PTEN Nasdaq
- Market Cap
- AGIO 2.1B
- PTEN 2.1B
- IPO Year
- AGIO 2013
- PTEN 1993
- Fundamental
- Price
- AGIO $36.39
- PTEN $5.50
- Analyst Decision
- AGIO Buy
- PTEN Buy
- Analyst Count
- AGIO 6
- PTEN 10
- Target Price
- AGIO $57.00
- PTEN $7.90
- AVG Volume (30 Days)
- AGIO 771.2K
- PTEN 7.8M
- Earning Date
- AGIO 10-30-2025
- PTEN 10-22-2025
- Dividend Yield
- AGIO N/A
- PTEN 5.92%
- EPS Growth
- AGIO N/A
- PTEN N/A
- EPS
- AGIO 11.13
- PTEN N/A
- Revenue
- AGIO $40,875,000.00
- PTEN $5,019,214,000.00
- Revenue This Year
- AGIO $28.19
- PTEN N/A
- Revenue Next Year
- AGIO $152.14
- PTEN N/A
- P/E Ratio
- AGIO $3.27
- PTEN N/A
- Revenue Growth
- AGIO 30.57
- PTEN N/A
- 52 Week Low
- AGIO $23.42
- PTEN $5.12
- 52 Week High
- AGIO $62.58
- PTEN $9.58
- Technical
- Relative Strength Index (RSI)
- AGIO 51.16
- PTEN 45.88
- Support Level
- AGIO N/A
- PTEN $5.40
- Resistance Level
- AGIO $37.18
- PTEN $5.70
- Average True Range (ATR)
- AGIO 1.43
- PTEN 0.24
- MACD
- AGIO -1.50
- PTEN -0.01
- Stochastic Oscillator
- AGIO 88.53
- PTEN 37.70
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About PTEN Patterson-UTI Energy Inc.
Patterson-UTI Energy Inc is one of the substantial land rig drilling contractors in the United States. Its 2023 merger with NexTier greatly expanded its pressure pumping operations, as well, and the firm now controls nearly 20% of the North American market for drilling and completions services. The company operates under three reportable business segments: (i) drilling services, (ii) completion services, and (iii) drilling products. It also provides directional drilling services and tool rental services in united states onshore oil and gas basins.